Persistence of Pneumococcal Serotype 3 in Adult Pneumococcal Disease in Hong Kong.
Reema SubramanianVeranja LiyanapathiranaNilakshi BaruaRui SunMaggie Haitian WangRita NgEdmund Anthony S NelsonDavid S HuiMargaret IpPublished in: Vaccines (2021)
The epidemiology of hospitalised pneumococcal disease in adults following the introduction of universal childhood pneumococcal immunisation in 2009 was assessed. Culture-confirmed Streptococcus pneumoniae (SP) from adults hospitalised between 2009 to 2017 were examined. The cases were categorised into invasive pneumococcal disease (IPD) and pneumonia (bacteraemic, non-bacteraemic, and that associated with other lung conditions). The isolates were serotyped and antimicrobial susceptibilities were determined by microbroth dilution. Patient characteristics, comorbidities, and outcomes were analysed. Seven hundred and seventy-four patients (mean age, 67.7 years, SD ± 15.6) were identified, and IPD was diagnosed in 110 (14.2%). The most prevalent serotype, 19F, was replaced by serotype 3 over time. Penicillin and cefotaxime non-susceptibilities were high at 54.1% and 39.5% (meningitis breakpoints), 19.9% and 25.5% (non-meningitis breakpoints), respectively. The overall 30-day mortality rate was 7.8% and 20.4% for IPD. Age ≥ 75 years (OR:4.6, CI:1.3-17.0, p < 0.02), presence of any complications (OR:4.1, CI:1.02-16.3, p < 0.05), pleural effusion (OR:6.7, CI:1.2-39.4, p < 0.03) and intensive care unit (ICU) admission (OR:9.0, CI:1.3-63.4, p < 0.03) were independent predictors of 30-day mortality. Pneumococcal disease by PCV 13 covered serotypes; in particular, 19F and 3 are still prominent in adults. Strengthening targeted adult vaccination may be necessary in order to reduce disease burden.
Keyphrases
- intensive care unit
- risk factors
- dengue virus
- end stage renal disease
- cardiovascular events
- chronic kidney disease
- staphylococcus aureus
- case report
- cardiovascular disease
- coronary artery disease
- adipose tissue
- zika virus
- klebsiella pneumoniae
- skeletal muscle
- drug delivery
- cancer therapy
- newly diagnosed
- young adults
- multidrug resistant
- genetic diversity